At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 18 May 2001 Profile reviewed but no significant changes made
- 18 May 2001 No-Development-Reported for Renal cancer in USA (Unknown route)